Trajetórias e emoção em uma instituição tecnocientífica argentina

A emoção é um campo de estudos complexo. Este texto apresenta elementos do debate sobre a sua abordagem teórica, empírica e disciplinar a partir de um recorte de material de terreno específico: entrevistas de trajetórias de pesquisadores que trabalham em uma instituição argentina de formação e produção de conhecimento científico e tecnológico. O texto colocará o foco nos termos que falam sobre emoções e nas narrativas que as exprimem. A hipótese é que esses termos e essas narrativas da emoção se constituem ferramentas analíticas para aprofundar a reflexão sobre as dinâmicas sociais que interpelam esses profissionais assim como sobre identidades ligadas ao trabalho, às experiências geracionais e aos contextos socioeconômicos e políticos específicos que eles habitam.Emotion is a complex study field. This text presents elements on the debate regarding its theoretical, empirical and disciplinary approach based on a snap of a specific field material : interviews regarding the trajectories of researchers who work in an Argentinian institution that creates and produces scientific and technologic knowledge. The text will focus on terms that talk about emotions and the narratives that carry them. The hypothesis is that these terms and narratives of emotion are constituted in analytical tools to deepen the reflection regarding social dynamics that permeate these professionals, as well as regarding identities connected to their work, their generational experiences and the specific socioeconomic and political they inhabit.Fil: Spivak L´hoste, Ana Silvia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Sociales. Instituto de Desarrollo Económico y Social. Centro de Investigaciones Sociales; Argentin

Consequences of the regular distribution of sainfoin hay on gastrointestinal parasitism with nematodes and on milk production in a dairy goat flock

The objectives of the current study were to examine the potential effects of distribution of sainfoin hay on nematode parasitism in a producing herd and to measure the consequences on milk production. The survey was performed in an experimental herd of 120-dairy-goat farm during a whole 9-month grazing season. Every month, 60 goats received indoors on average 1.36 kg of sainfoin hay for 10 days whereas the 60 remaining goats were used as controls, thus receiving the same amount of lucerne hay at the same time. The nutritional values of both hays were comparable except that concentrations of condensed tannins was higher in sainfoin than in lucerne hay, i.e. 2.52% versus 0.7% of diet DM. Intakes of the two types of hay were recorded along with each period. Individual faecal and blood samples were performed monthly to compare parasitological and pathophysiological parameters in the two groups. Milk yield, fat and protein contents were measured fortnightly. A higher consumption of hay was repeatedly recorded in the sainfoin versus the control group. Irrespective to dietary treatment, nematode egg excretions were low during the whole season. Meanwhile, egg output was significantly lowest in the sainfoin group, but the composition in nematode genera was similar among the two groups. Based on a semi quantitative index for assessment of faecal consistency, a lower faecal dry matter content was also found in goats from the sainfoin group. The two animal groups exhibited similar milk yield, fat and protein contents. The differences in egg excretion between the two groups might be due to higher intake of hay in the barn thus to low consumption of grass, a source of parasite infection, or to the effect of some secondary compounds, like tannins. Whatever the mechanism involved, our results suggest that a regular distribution of sainfoin hay to dairy goats might be associated with a reduction in parasitism with gastrointestinal nematodes, without negative consequences on milk production. © 2005 Elsevier B.V. All rights reserved

Do acute elevations of serum creatinine in primary care engender an increased mortality risk?

Background: The significant impact Acute Kidney Injury (AKI) has on patient morbidity and mortality emphasizes the need for early recognition and effective treatment. AKI presenting to or occurring during hospitalisation has been widely studied but little is known about the incidence and outcomes of patients experiencing acute elevations in serum creatinine in the primary care setting where people are not subsequently admitted to hospital. The aim of this study was to define this incidence and explore its impact on mortality. Methods: The study cohort was identified by using hospital data bases over a six month period. Inclusion criteria: People with a serum creatinine request during the study period, 18 or over and not on renal replacement therapy. The patients were stratified by a rise in serum creatinine corresponding to the Acute Kidney Injury Network (AKIN) criteria for comparison purposes. Descriptive and survival data were then analysed. Ethical approval was granted from National Research Ethics Service (NRES) Committee South East Coast and from the National Information Governance Board. Results: The total study population was 61,432. 57,300 subjects with ‘no AKI’, mean age 64.The number (mean age) of acute serum creatinine rises overall were, ‘AKI 1’ 3,798 (72), ‘AKI 2’ 232 (73), and ‘AKI 3’ 102 (68) which equates to an overall incidence of 14,192 pmp/year (adult). Unadjusted 30 day survival was 99.9% in subjects with ‘no AKI’, compared to 98.6%, 90.1% and 82.3% in those with ‘AKI 1’, ‘AKI 2’ and ‘AKI 3’ respectively. After multivariable analysis adjusting for age, gender, baseline kidney function and co-morbidity the odds ratio of 30 day mortality was 5.3 (95% CI 3.6, 7.7), 36.8 (95% CI 21.6, 62.7) and 123 (95% CI 64.8, 235) respectively, compared to those without acute serum creatinine rises as defined. Conclusions: People who develop acute elevations of serum creatinine in primary care without being admitted to hospital have significantly worse outcomes than those with stable kidney function

Acute kidney disease and renal recovery : consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup

Consensus definitions have been reached for both acute kidney injury (AKI) and chronic kidney disease (CKD) and these definitions are now routinely used in research and clinical practice. The KDIGO guideline defines AKI as an abrupt decrease in kidney function occurring over 7 days or less, whereas CKD is defined by the persistence of kidney disease for a period of > 90 days. AKI and CKD are increasingly recognized as related entities and in some instances probably represent a continuum of the disease process. For patients in whom pathophysiologic processes are ongoing, the term acute kidney disease (AKD) has been proposed to define the course of disease after AKI; however, definitions of AKD and strategies for the management of patients with AKD are not currently available. In this consensus statement, the Acute Disease Quality Initiative (ADQI) proposes definitions, staging criteria for AKD, and strategies for the management of affected patients. We also make recommendations for areas of future research, which aim to improve understanding of the underlying processes and improve outcomes for patients with AKD

Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications

This article reports the conclusions of the second part of a consensus expert conference on the nomenclature of renal replacement therapy (RRT) techniques currently utilized to manage acute kidney injury and other organ dysfunction syndromes in critically ill patients. A multidisciplinary approach was taken to achieve harmonization of definitions, components, techniques, and operations of the extracorporeal therapies. The article describes the RRT techniques in detail with the relevant technology, procedures, and phases of treatment and key aspects of volume management/fluid balance in critically ill patients. In addition, the article describes recent developments in other extracorporeal therapies, including therapeutic plasma exchange, multiple organ support therapy, liver support, lung support, and blood purification in sepsis. This is a consensus report on nomenclature harmonization in extracorporeal blood purification therapies, such as hemofiltration, plasma exchange, multiple organ support therapies, and blood purification in sepsis

Ninth and Tenth Order Virial Coefficients for Hard Spheres in D Dimensions

We evaluate the virial coefficients B_k for k<=10 for hard spheres in dimensions D=2,...,8. Virial coefficients with k even are found to be negative when D>=5. This provides strong evidence that the leading singularity for the virial series lies away from the positive real axis when D>=5. Further analysis provides evidence that negative virial coefficients will be seen for some k>10 for D=4, and there is a distinct possibility that negative virial coefficients will also eventually occur for D=3.Comment: 33 pages, 12 figure

Quantum Gravity and the Algebra of Tangles

In Rovelli and Smolin's loop representation of nonperturbative quantum gravity in 4 dimensions, there is a space of solutions to the Hamiltonian constraint having as a basis isotopy classes of links in R^3. The physically correct inner product on this space of states is not yet known, or in other words, the *-algebra structure of the algebra of observables has not been determined. In order to approach this problem, we consider a larger space H of solutions of the Hamiltonian constraint, which has as a basis isotopy classes of tangles. A certain algebra T, the ``tangle algebra,'' acts as operators on H. The ``empty state'', corresponding to the class of the empty tangle, is conjectured to be a cyclic vector for T. We construct simpler representations of T as quotients of H by the skein relations for the HOMFLY polynomial, and calculate a *-algebra structure for T using these representations. We use this to determine the inner product of certain states of quantum gravity associated to the Jones polynomial (or more precisely, Kauffman bracket).Comment: 16 pages (with major corrections

A unified Witten-Reshetikhin-Turaev invariant for integral homology spheres

We construct an invariant J_M of integral homology spheres M with values in a completion \hat{Z[q]} of the polynomial ring Z[q] such that the evaluation at each root of unity \zeta gives the the SU(2) Witten-Reshetikhin-Turaev invariant \tau_\zeta(M) of M at \zeta. Thus J_M unifies all the SU(2) Witten-Reshetikhin-Turaev invariants of M. As a consequence, \tau_\zeta(M) is an algebraic integer. Moreover, it follows that \tau_\zeta(M) as a function on \zeta behaves like an ``analytic function'' defined on the set of roots of unity. That is, the \tau_\zeta(M) for all roots of unity are determined by a "Taylor expansion" at any root of unity, and also by the values at infinitely many roots of unity of prime power orders. In particular, \tau_\zeta(M) for all roots of unity are determined by the Ohtsuki series, which can be regarded as the Taylor expansion at q=1.Comment: 66 pages, 8 figure

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort

BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. METHODS: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. RESULTS: SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced 651 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with 651 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not 655. CONCLUSIONS: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginterferon alfa-2a/ribavirin